Trillium Therapeutics shares soar on Pfizer’s $2.26B deal
Pfizer's $2.26B Trillium deal will target drugs for blood cancers, such as leukemia, multiple myeloma and lymphoma, according to the companies.
https://ift.tt/382GaOd
Subscribe to:
Post Comments
(
Atom
)
Post a Comment